RT Journal Article
T1 Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.
A1 Lin, Chunqing
A1 Slama, Jiri
A1 Gonzalez, Paula
A1 Goodman, Marc T
A1 Xia, Ningshao
A1 Kreimer, Aimée R
A1 Wu, Ting
A1 Hessol, Nancy A
A1 Shvetsov, Yurii
A1 Ortiz, Ana P
A1 Grinsztejn, Beatriz
A1 Moscicki, Anna-Barbara
A1 Heard, Isabelle
A1 Del Refugio González Losa, María
A1 Kojic, Erna M
A1 Schim van der Loeff, Maarten F
A1 Wei, Feixue
A1 Longatto-Filho, Adhemar
A1 Mbulawa, Zizipho A
A1 Palefsky, Joel M
A1 Sohn, Annette H
A1 Hernandez, Brenda Y
A1 Robison, Katina
A1 Simpson, Steve
A1 Conley, Lois J
A1 de Pokomandy, Alexandra
A1 van der Sande, Marianne A B
A1 Dube Mandishora, Racheal S
A1 Volpini, Lays P B
A1 Pierangeli, Alessandra
A1 Romero, Byron
A1 Wilkin, Timothy
A1 Franceschi, Silvia
A1 Hidalgo-Tenorio, Carmen
A1 Ramautarsing, Reshmie A
A1 Park, Ina U
A1 Tso, Fernanda K
A1 Godbole, Sheela
A1 D'Hauwers, Kathleen W M
A1 Sehnal, Borek
A1 Menezes, Lynette J
A1 Heráclio, Sandra A
A1 Clifford, Gary M
AB Cervical cancer screening might contribute to the prevention of anal cancer in women. We aimed to investigate if routine cervical cancer screening results-namely high-risk human papillomavirus (HPV) infection and cytohistopathology-predict anal HPV16 infection, anal high-grade squamous intraepithelial lesions (HSIL) and, hence, anal cancer. We did a systematic review of MEDLINE, Embase, and the Cochrane library for studies of cervical determinants of anal HPV and HSIL published up to Aug 31, 2018. We centrally reanalysed individual-level data from 13 427 women with paired cervical and anal samples from 36 studies. We compared anal high-risk HPV prevalence by HIV status, cervical high-risk HPV, cervical cytohistopathology, age, and their combinations, using prevalence ratios (PR) and 95% CIs. Among 3255 women with anal cytohistopathology results, PRs were similarly calculated for all anal HSIL and HPV16-positive anal HSIL. Cervical and anal HPV infections were highly correlated. In HIV-negative women, anal HPV16 prevalence was 41% (447/1097) in cervical HPV16-positive versus 2% (214/8663) in cervical HPV16-negative women (PR 16·5, 95% CI 14·2-19·2, p HPV-based cervical cancer screening programmes might help to stratify anal cancer risk, irrespective of HIV status. For targeted secondary anal cancer prevention in high-risk groups, HIV-negative women with cervical HPV16, especially those older than 45 years, have a similar anal cancer risk profile to that of HIV-positive women. International Agency for Research on Cancer.
YR 2019
FD 2019-06-13
LK http://hdl.handle.net/10668/14122
UL http://hdl.handle.net/10668/14122
LA en
DS RISalud
RD May 9, 2025